Abstract 990P
Background
Hepatic arterial infusion chemotherapy (HAIC) is known to be more effective than conventional systemic chemotherapy, showing great potential in treating unresectable hepatocellular carcinoma (HCC) patients. However, there is still unclear which group can benefit more from HAIC.
Methods
191 patients with unresectable HCC undergoing HAIC from Zhongshan Hospital between May 2019 and March 2022 were retrospectively recruited. Radiomics scores were calculated based on enhanced-T1-weighted, enhanced-T2-weighted, arterial phase and delayed phase images. Clinical factors related to OS and PFS were identified by Cox regression analysis. Three different CNNs of AlexNet, ResNet, and Inception architectures were constructed on 70% of the data set and tested on the remaining 30%. Radiomics scores and clinical factors were reflected to a model eventually. Mean squared error (MSE) and time-dependent receiver operating characteristic curve were calculated for the models.
Results
The OS model included radiomics score with No. of HAIC cycles, tumor thrombus, PIVKA-II, neutrophil-lymphocyte ratio (NLR), aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (γ-GT) and C-reactive protein. And the PFS model included radiomics score with No. of HAIC cycles, tumor thrombus, NLR and γ-GT. The AlexNet-OS model, ResNet-OS model, and Inception-OS model achieved the best MSE of 1.0068, 0.9023 and 0.8506, respectively. The AlexNet-PFS model, ResNet- PFS model, and Inception- PFS model achieved the best MSE of 0.6658, 0.6819 and 1.1012, respectively.
Conclusions
The present models which integrated radiomics information and clinical factors helped predict OS and PFS of unresectable HCC patients undergoing HAIC treatment.
Clinical trial identification
Editorial acknowledgement
We are very grateful to Mrs. Hailin Mi for helping us to construct the deep learning model. Hailin Mi kindly provided statistical advice for this manuscript. (Hailin Mi; Department of Computer Science and Technology, Harbin Engineering University, China)
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China (No. 81972889, Dr Yin).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18